[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Armstrong TS, Vera-Bolanos E, Bekele BN, Aldape K, Gilbert MR: Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. Neuro Oncol; 2010 Aug;12(8):862-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience.
  • This study reports on a series of adult patients with confirmed ependymoma treated at The University of Texas M. D.
  • This series included 123 adult patients [51% male; median age 39 years (18-72)].
  • Forty had tumors in the brain, 80 in the spine, and 3 had both.
  • Eighteen patients had tumors that were reclassified as ependymal tumors at MDACC.
  • Median time to recurrence was 21 months (Grade II) brain and 18 months (Grade III).
  • Worse outcome measured by overall and progression-free survival were associated with brain location (P = .01, P = .04) and tumor anaplasia (P = .0025, P = .001).
  • Tumor grade and brain location are associated with a worse prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neurosurgical Procedures. Prognosis. Proportional Hazards Models. Radiotherapy. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):542-53 [11013626.001]
  • [Cites] J Neurosurg. 2009 Apr;110(4):725-9 [19061350.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1221-9 [15022290.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1457-62 [3624024.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):283-90 [1517804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Pediatr Neurosurg. 1998 Jan;28(1):49-55 [9693331.001]
  • [Cites] Radiographics. 2005 Mar-Apr;25(2):486-90 [15798065.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1):E192; discussion E192 [15987557.001]
  • [Cites] Brain. 2007 May;130(Pt 5):1338-49 [17449478.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):81-9 [17482475.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):307-16 [18532929.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jan;52(1):65-9 [19006249.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • (PMID = 20511182.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC2940672
  •  go-up   go-down


2. Lehman NL: Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors. J Neuropathol Exp Neurol; 2008 Sep;67(9):900-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors.
  • Ependymomas are generally considered to be noninfiltrative tumors that have discrete borders with adjacent brain tissue.
  • Supratentorial ependymal tumors arise near the ventricular system or, more rarely, within the cerebral white matter or cortex.
  • Presented here are 6 supratentorial ependymal tumors, 3 that primarily involve the cerebral cortex and 3 that extend into the cortex from the underlying white matter.
  • By microscopy, all of these tumors locally infiltrate the cortex and/or white matter along small blood vessels and axonal fiber tracts.
  • They also form other glioma secondary structures including perineuronal tumor cell satellitosis and subpial tumor cell mounds.
  • The 3 cortical ependymal tumors show a spectrum of features ranging from conventional and clear-cell ependymoma-like patterns to more angiocentric glioma-like histology.
  • Because ependymal tumors generally have a significantly better prognosis than other infiltrating gliomas, recognition of their capacity to infiltrate adjacent cortex and white matter is important to prevent the misdiagnosis of oligodendroglioma, astrocytoma, or infiltrating glioma, not otherwise specified.
  • Cortical ependymomas and angiocentric gliomas may comprise a group of locally infiltrative ependymal tumors that are associated with an excellent prognosis after gross total surgical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2000 Mar;16(3):170-5 [10804053.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Mar;67(3):177-88 [18344909.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Pediatr Neurosurg. 2003 Jul;39(1):50-4 [12784079.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):357-62 [12898154.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):914-20 [15223962.001]
  • [Cites] J Neuropathol Exp Neurol. 1978 Mar-Apr;37(2):103-18 [632843.001]
  • [Cites] Int Rev Cytol. 1985;96:121-55 [2416706.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):67-74 [7709787.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] No Shinkei Geka. 1999 Sep;27(9):843-6 [10478346.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1):E192; discussion E192 [15987557.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Oct;64(10):875-81 [16215459.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):281-6 [16389940.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):388-95 [16342252.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):313-24 [17061076.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1709-18 [18059228.001]
  • [Cites] Neuropathology. 2008 Feb;28(1):81-6 [18021197.001]
  • [Cites] Pediatr Neurosurg. 2001 Feb;34(2):77-87 [11287807.001]
  • (PMID = 18716554.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS045077; United States / NINDS NIH HHS / NS / NS045077-05; United States / NINDS NIH HHS / NS / K08 NS045077-05; United States / NINDS NIH HHS / NS / K08 NS45077
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS131630; NLM/ PMC2805172
  •  go-up   go-down


3. Brandes AA, Cavallo G, Reni M, Tosoni A, Nicolardi L, Scopece L, Franceschi E, Sotti G, Talacchi A, Turazzi S, Ermani M: A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer; 2005 Jul 1;104(1):143-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.
  • BACKGROUND: No data on the role of chemotherapy in recurrent ependymal tumors are available in adults.
  • METHODS: A retrospective review was made of the charts of 28 adults (> or = 18 years) with progressive or recurrent ependymal tumors after surgery and radiotherapy, who received chemotherapy between 1993 and 2003 in 3 institutions of the Gruppo Italiano Cooperativo di Neuro-Oncologia network.
  • More active regimens for the salvage treatment of ependymal tumors have yet to be found.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Ependymoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Italy. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912507.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Palm T, Figarella-Branger D, Chapon F, Lacroix C, Gray F, Scaravilli F, Ellison DW, Salmon I, Vikkula M, Godfraind C: Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis. Cancer; 2009 Sep 1;115(17):3955-68
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of ependymomas unravels localization and tumor grade-specific tumorigenesis.
  • BACKGROUND: Ependymomas derive from ependymal cells that cover the cerebral ventricles and the central canal of the spinal cord.
  • METHODS: The authors performed array-based expression profiling on a series of 34 frozen ependymal tumors with different localizations and histologic grades.
  • RESULTS: Class discovery experiments indicated a strong correlation between profiles and tumor localization as well as World Health Organization (WHO) tumor grades.
  • CONCLUSIONS: Taken together, the tumor localization-related gene sets mainly implicated in stem cell maintenance, renewal, and differentiation suggest the dysregulation of localized cancer stem cells during ependymoma development.
  • On the basis of the current data, the authors suggest a developmental scheme of ependymomas that integrates tumor localization and tumor grades, and that pinpoints new targets for the development of future therapeutic approaches.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Ependymoma / genetics. Ependymoma / pathology. Gene Expression Profiling
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic. Child. Child, Preschool. Humans. Infant. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536879.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R: Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol; 2009 Dec;22(12):1600-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
  • It is unclear how annexin-1 is expressed in various neuroepithelial tumors, and whether there is any association with tumor malignancy or survival.
  • We studied annexin-1 expression in 394 glial neoplasms of all grades of malignancy and 81 normal brain samples by immunohistochemistry using tissue microarrays.
  • In the normal human brain, the expression of annexin-1 is limited to ependymal cells and subependymal astrocytes, but is also upregulated in reactive astrocytes.
  • In addition, nuclear staining of annexin-1 in oligodendroglial tumor cells was significantly reduced (P=0.0002), which may be used as a diagnostic tool for differentiating between astrocytomas and oligodendrogliomas.
  • Although annexin-1 expression in ependymomas decreased with the grade of malignancy, diffuse astrocytomas showed a significant increase in cytoplasmic annexin-1-positive tumor cells.
  • Thus, annexin-1 upregulation in astrocytomas may contribute to tumor progression and its expression profile is similar to its substrate, EGFR, suggesting a possible regulation thereof.
  • [MeSH-major] Annexin A1 / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Glioma / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / chemistry. Blotting, Western. Cell Nucleus / chemistry. Child. Child, Preschool. Ependymoma / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / chemistry. Prognosis. Receptor, Epidermal Growth Factor / analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Time Factors. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767728.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


6. Rousseau E, Palm T, Scaravilli F, Ruchoux MM, Figarella-Branger D, Salmon I, Ellison D, Lacroix C, Chapon F, Mikol J, Vikkula M, Godfraind C: Trisomy 19 ependymoma, a newly recognized genetico-histological association, including clear cell ependymoma. Mol Cancer; 2007;6:47
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymal tumors constitute a clinicopathologically heterogeneous group of brain tumors.
  • We define a newly recognized subset of ependymal tumors, the trisomy 19 ependymoma.
  • Most trisomy 19 ependymomas are supratentorial WHO grade III tumors of the young.
  • Recognition of this genetico-histological entity allows better understanding and dissection of ependymal tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Chromosomes, Human, Pair 19 / genetics. Ependymoma / pathology. Trisomy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 9 / genetics. Female. Genome, Human. Humans. Infant. Male. Microsatellite Repeats / genetics. Middle Aged. Nucleic Acid Hybridization / methods. Polymorphism, Single Nucleotide. Tissue Array Analysis / methods. Tissue Fixation / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1994 Oct 7;79(1):119-30 [7923370.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):141-52 [12790776.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):820-6 [9236838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11268-73 [9326598.001]
  • [Cites] Surg Neurol. 1999 Mar;51(3):281-7; discussion 287-8 [10086492.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):361-8 [15781323.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3542-7 [15867346.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Oct;29(5):462-71 [14507338.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2232-44 [14601094.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Dec;29(6):574-83 [14636164.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):9-14 [14631364.001]
  • [Cites] Bioinformatics. 2004 May 22;20(8):1233-40 [14871870.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):24-30 [15108012.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9527-41 [15485920.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1989;415(5):467-72 [2477945.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):7953-65 [16135788.001]
  • [Cites] Cancer Biol Ther. 2005 Nov;4(11):1216-21 [16357509.001]
  • [Cites] Genomics. 2006 Feb;87(2):298-306 [16271290.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6664-72 [16317011.001]
  • [Cites] Calcif Tissue Int. 2006 Apr;78(4):233-40 [16604287.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):268-76 [16645215.001]
  • [Cites] J Biol Chem. 2006 May 26;281(21):14711-8 [16595680.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):391-400 [16764692.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):958-62 [16648869.001]
  • [Cites] Lab Invest. 2006 Sep;86(9):968-78 [16751780.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] J Mol Med (Berl). 2007 Mar;85(3):293-304 [17143621.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):73-84 [10668897.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1137-43 [11238062.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46460-8 [11585837.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1109-19 [11106750.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):929-39 [11953826.001]
  • [Cites] Mod Pathol. 2002 May;15(5):526-31 [12011257.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • (PMID = 17626628.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1950527
  •  go-up   go-down


7. Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD: Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer; 2005 Jun 15;103(12):2598-605
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
  • BACKGROUND: Published research on the clinicopathologic features of extraventricular ependymal neoplasms of the cerebral hemispheres has been scant.
  • Tumors expressed glial fibrillary acidic protein (87%), S-100 protein (77%), cytokeratin (43%), and epithelial membrane antigen (17%).
  • Ki-67 proliferation index paralleled tumor grade.
  • Flow cytometry performed in 27 tumors revealed diploidy in 20 cases and aneuploidy in 4 cases (3 anaplastic and 1 classic ependymomas), with S-phase fraction ranging from 0.2-9.7.
  • CONCLUSIONS: The results of the current study suggest that there is no significant relation between histopathology, Ki-67 proliferation index, p53 immunolabeling, tumor ploidy, and biologic behavior.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Ploidies. Prognosis. S Phase. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 by the American Cancer Society.
  • (PMID = 15861411.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Roma AA, Prayson RA: Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology; 2006 Oct;26(5):422-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclo-oxygenase-2 in ependymal tumors.
  • Up-regulation of cyclo-oxygenase-2 (COX-2), a cytokine-induced enzyme that metabolizes arachidonic acid into prostaglandins, has been described in some brain tumors, including astrocytomas.
  • Little is known about its expression in ependymal neoplasms.
  • The objective of the present study was to assess COX-2 immunostaining of ependymal tumors.
  • Retrospective COX-2 immunohistochemical analysis was conducted on 117 ependymal tumors.
  • At last known follow-up (range, 12-226 months; mean, 74 months), 52 patients were alive with no evidence of tumor, 16 patients were alive with residual tumor, nine patients died with tumor, one patient died with no tumor and three died with tumor status unknown.
  • Thirty-six (36%) patients had tumors, which demonstrated positive COX-2 staining, including 16/27 (59%) myxopapillary ependymomas, 3/13 (23%) subependymomas, 14/48 (29%) ependymomas and 3/12 (25%) anaplastic ependymomas.
  • Statistically significant COX-2 positive immunostaining was observed in myxopapillary ependymomas versus WHO grade II (P = 0.03) and grade III (P = 0.02) tumors.
  • The reason for this apparent increased immunoexpression in these low-grade tumors is uncertain.
  • COX-2 inhibitors may play a role in treatment of the subset of ependymal tumors that demonstrate increased expression.
  • COX-2 staining did not reliably predict tumor behavior.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cyclooxygenase 2 / biosynthesis. Ependymoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080719.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


9. Rodriguez FJ, Scheithauer BW, Perry A, Oliveira AM, Jenkins RB, Oviedo A, Mork SJ, Palmer CA, Burger PC: Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study. Am J Surg Pathol; 2008 May;32(5):699-709
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study.
  • Gliosarcomas are uncommon primary tumors of the central nervous system defined as exhibiting both glial and sarcomatous components.
  • Sarcomatous change occurring in ependymal tumors is rare.
  • The tumors were located in the parieto-occipital (n=2), temporal (n=1), parietal (n=1), frontal (n=1), and occipital lobes (n=1), as well as the lateral ventricles (n=2), insula (n=1), cerebellopontine angle (n=1), and fourth ventricle/cerebellopontine angle (n=1).
  • At presentation, the sarcomatous component was noted in 6 (of 10) cases and the ependymal element was grade III in 7 and grade II in 3 tumors, respectively.
  • Fluorescence in situ hybridization studies performed with probes targeting the NF2 gene and other members of the protein 4.1 gene family demonstrated similar alterations in the ependymal and sarcomatous components in the cases tested, including polysomies/polyploidy (n=3), gains of 1q (n=3), deletions of 22q (n=2) and 6q (n=1), and monosomy 18 (n=1).
  • Although rare, ependymal neoplasms must be included among the gliomas prone to undergo sarcomatous change and we propose the term "ependymosarcoma" for these tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / secondary. Fibrosarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Combined Modality Therapy. DNA, Neoplasm / analysis. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347506.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


10. Gibson SE, Zeng WF, Weil RJ, Prayson RA: Aurora B kinase expression in ependymal neoplasms. Appl Immunohistochem Mol Morphol; 2008 May;16(3):274-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aurora B kinase expression in ependymal neoplasms.
  • Overexpression of Aurora B kinase, which regulates cell progression through mitosis and cytokinesis, has been shown to be associated with higher-grade tumors and shortened survival in astrocytomas.
  • The association between Aurora B expression and World Health Organization grade II/III tumors was statistically significant (P<0.0001).
  • Aurora B expression was not associated with patient age, sex, tumor location, tumor recurrence, or death from tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301241.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


11. Fèvre-Montange M, Champier J, Szathmari A, Wierinckx A, Mottolese C, Guyotat J, Figarella-Branger D, Jouvet A, Lachuer J: Microarray analysis reveals differential gene expression patterns in tumors of the pineal region. J Neuropathol Exp Neurol; 2006 Jul;65(7):675-84
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray analysis reveals differential gene expression patterns in tumors of the pineal region.
  • Several types of tumors are known to originate from the pineal region, among them pineal parenchymal tumors (PPTs) and papillary tumors of the pineal region (PTPRs), probably derived from the subcommissural organ.
  • To identify molecular markers, using CodeLink oligonucleotide arrays, gene expression was studied in 3 PPTs (2 pineocytomas and one pineoblastoma), 2 PTPRs, and one chordoid glioma, another rare tumor of the third ventricle.
  • Because PTPR and chordoid glioma may present ependymal differentiation, gene expression was also analyzed in 4 ependymomas.
  • Our results highlight the usefulness of gene expression profiling for classify tumors of the pineal region and identify genes with potential use as diagnostic markers.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression Profiling / utilization. Gene Expression Regulation. Pineal Gland. Pinealoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cluster Analysis. Female. Humans. Infant. Male. Middle Aged. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825954.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Dagnew E, Langford LA, Lang FF, DeMonte F: Papillary tumors of the pineal region: case report. Neurosurgery; 2007 May;60(5):E953-5; discussion E953-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary tumors of the pineal region: case report.
  • On review, these papillary, keratin-positive neoplasms meet the criteria for papillary tumor of the pineal region (PTPR).
  • CONCLUSION: The morphological features of the tumors in our series, along with the clinical presentations, are similar to those in the original description of the PTPR.
  • Our findings agree with the original hypothesis that the cells composing the PTPR are similar to ependymal cells of the subcommissural organ, thus furthering the hypothesis that the PTPR derives from a specialized ependymocyte associated with the subcommissural organ.
  • [MeSH-major] Brain Neoplasms / diagnosis. Pineal Gland / pathology. Pinealoma / diagnosis
  • [MeSH-minor] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / surgery. Adult. Diagnosis, Differential. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460510.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Maiuri F, Del Basso De Caro M, Siciliano A, Peca C, Vergara P, Mariniello G, Pettinato G: Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival. Clin Neuropathol; 2010 Mar-Apr;29(2):109-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
  • OBJECTIVE: The aim of this study is to evaluate the correlation between the expression of some growth factors (GFs) and the tumor grade, recurrence and survival of brain glial and ependymal tumors.
  • MATERIAL AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), tenascine, transforming growth factor (TGFbeta), isomeres, platelet-derived growth factor (PDGF) and p53 was studied in 40 primary brain tumors, both low-grade and high-grade, including astrocytomas, oligodendrogliomas, glioblastomas and ependymomas.
  • The same GFs were also studied in 46 specimens of recurrent tumors from the same patients.
  • The positivity and intensity of the immunohistochemical expression were correlated with the tumor grade, the interval and type of recurrence, and the survival.
  • RESULTS: The expression of all GFs, excepting TGFbeta1, TGFbetaRI and tenascine, was found to be correlated with the tumor grade in all tumors of both astroglial and oligodendroglial origin, whereas ependymomas showed significant differences only for EGFR.
  • Low-grade (Grade II) tumors recurring as anaplastic (Grade III) forms showed GF expression rather similar to initially high-grade gliomas and significantly higher than that of low-grade (Grade II) tumors in both initial surgery and recurrence.
  • Besides, low-grade (Grade II) tumors recurring as low-grade showed significantly longer median recurrence time (5.4 vs. 3.5 years) and better median survival (8.3 vs. 5.4 years) than those recurring as anaplastic forms (WHO III).
  • CONCLUSION: The immunohistochemical study of expression of VEGF, EGFR, TGFbeta2, TGFbeta3, PDGF and p53 in all low-grade (Grade II) brain gliomas at the first operation may help to differentiate cases with slower evolution and longer survival from those with higher potential of anaplastic transformation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Intercellular Signaling Peptides and Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175962.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


14. Phi JH, Park SH, Kim SK, Paek SH, Kim JH, Lee YJ, Cho BK, Park CK, Lee DH, Wang KC: Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol; 2008 Jan;32(1):103-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway.
  • Moreover, it was recently found that brain tumors contain stem cells that resemble normal neuroglial stem cells in many respects.
  • This study was undertaken to describe Sox2 expression in various brain tumors, and to determine whether Sox2 expression is a universal feature of brain tumors, or whether its expression is limited to a specific lineage of brain tumors.
  • Sox2 immunohistochemistry was performed on 194 brain tumor tissues of various kinds.
  • Fetal and adult normal brain tissues obtained by autopsy and brain tissues of epilepsy patients with cortical dysplasia were used as controls.
  • Sox2 was found to be expressed in various glial tumors, including those with astroglial, oligodendroglial, and ependymal lineages, and in the glial components of mixed neuroglial tumors, regardless of pathologic grade.
  • In brain tumors of embryonal origin, supratentorial primitive neuroectodermal tumors showed robust Sox2 expression, whereas medulloblastomas and pineoblastomas did not.
  • The majority of Sox2-positive tumor cells coexpressed glial fibrillary acidic protein, and most Sox2-negative cells in medulloblastomas and pineoblastomas showed neuronal differentiation.
  • This study suggest that Sox2 may be a tumor marker of glial lineages rather than a universal brain tumor stem cell marker, because its expression pattern was found to correspond to differentiation pathways.
  • On the other hand, the aberrant coexpressions of Sox2 and of a neuronal marker were widely observed in glioblastomas, which reflects a disorganized differentiation pattern that characterizes highly malignant tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. HMGB Proteins / biosynthesis. Neuroglia / cytology. Neuroglia / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Brain / cytology. Brain / embryology. Brain / metabolism. Cell Differentiation. Cell Lineage. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. SOXB1 Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162777.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / HMGB Proteins; 0 / RNA, Messenger; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


15. Santi M, Quezado M, Ronchetti R, Rushing EJ: Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization. J Neurooncol; 2005 Mar;72(1):25-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of chromosome 7 in adult and pediatric ependymomas using chromogenic in situ hybridization.
  • Few studies have yielded reliable data that distinguish between ependymal neoplasms based on molecular genetic attributes.
  • The present study utilizes chromogenic in situ hybridization (CISH), a relatively recent hybridization technique, to retrospectively examine chromosome 7-copy number in pediatric and adult ependymomas.
  • Of the 27 hybridizations, polysomy of chromosome 7 was detected in 10 out of 15 (66%) adult ependymomas, and in only three out of 12 (25%) pediatric lesions.
  • The remaining tumors were diploid.
  • The authors conclude that (1) there are distinct genetic subsets of ependymoma, in particular, increases in copy number of chromosome 7 are almost exclusively found in myxopapillary ependymoma, and that (2) CISH is a rapid and sensitive method of stratifying morphological variants of ependymoma and potentially other central nervous system (CNS) tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 7 / genetics. Ependymoma / genetics. Ploidies. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Chromogenic Compounds / analysis. Humans. In Situ Hybridization / methods. Infratentorial Neoplasms / classification. Infratentorial Neoplasms / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803371.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogenic Compounds
  •  go-up   go-down


16. Hasselblatt M, Böhm C, Tatenhorst L, Dinh V, Newrzella D, Keyvani K, Jeibmann A, Buerger H, Rickert CH, Paulus W: Identification of novel diagnostic markers for choroid plexus tumors: a microarray-based approach. Am J Surg Pathol; 2006 Jan;30(1):66-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel diagnostic markers for choroid plexus tumors: a microarray-based approach.
  • To identify specific markers for the diagnosis of choroid plexus tumors, gene expression profiles of choroid plexus epithelial cells (n = 8) and ependymal cells (n = 6) microdissected from human autopsy brains as well as choroid plexus papilloma tissue were investigated using DNA microarrays.
  • Protein expression of genes overexpressed in choroid plexus was evaluated in normal choroid plexus, choroid plexus papilloma, choroid plexus carcinoma, other primary brain tumors, and cerebral metastases.
  • Expression of inward rectifier potassium channel Kir7.1 was confirmed in normal choroid plexus (34 of 35), choroid plexus papilloma (12 of 18), and choroid plexus carcinoma (5 of 5) but was not found in 100 other primary brain tumors and cerebral metastases.
  • Similarly, stanniocalcin-1 stained normal choroid plexus (32 of 35), choroid plexus papilloma (16 of 18), and choroid plexus carcinoma (3 of 5), whereas staining was seen in only 2 of 100 other primary brain tumors and cerebral metastases.
  • Our data suggest that antibodies directed against Kir7.1 and stanniocalcin-1 might serve as sensitive and specific diagnostic markers for choroid plexus tumors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Choroid Plexus Neoplasms / diagnosis. Papilloma, Choroid Plexus / diagnosis
  • [MeSH-minor] Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Diagnosis, Differential. Ependyma / metabolism. Ependyma / pathology. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Gene Expression. Gene Expression Profiling. Glycoproteins / metabolism. Humans. Immunohistochemistry. Oligonucleotide Array Sequence Analysis. Potassium Channels, Inwardly Rectifying / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330944.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Kir7.1 channel; 0 / Potassium Channels, Inwardly Rectifying; 76687-96-2 / teleocalcin
  •  go-up   go-down


17. De Tommasi A, De Tommasi C, Occhiogrosso G, Cimmino A, Parisi M, Sanguedolce F, Ciappetta P: Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature. Eur J Neurol; 2006 Mar;13(3):240-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature.
  • Spinal primitive neuroectodermal tumors (PNET) are very rare tumors, and intramedullary localization is even less common.
  • Following the WHO 2000 classification, PNETs have been considered embryonal tumors composed of undifferentiated neuroepithelial cells with a capacity of differentiation into different cellular lines, such as astrocytic, ependymal, melanotic and muscular.
  • The optimal treatment for these malignant tumors is not yet clear, although, over the years, radiotherapy has been considered the best treatment for spinal PNETs.
  • The patient, 18 months after the onset of his symptomatology, died without cerebral tumor involvement.
  • [MeSH-major] Brain Neoplasms. Laminectomy / methods. Neuroectodermal Tumors, Primitive
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618339.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


18. Amini A, Schmidt RH, Salzman KL, Chin SS, Couldwell WT: Glioblastoma multiforme of the pineal region. J Neurooncol; 2006 Sep;79(3):307-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBMs) tumors are exceedingly rare tumors in the pineal region.
  • Pineal region GBM seems to be a very aggressive tumor with a high rate of leptomeningeal and ependymal metastatic disease.
  • Glioblastoma should be considered in the differential diagnosis of the pineal region tumors, especially when evidence of leptomeningeal or ependymal metastatic disease is present.
  • [MeSH-major] Brain / pathology. Glioblastoma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nausea / etiology. Tomography, X-Ray Computed. Vision Disorders / etiology. Vomiting / etiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645719.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Katoh N, Shirato H, Aoyama H, Onimaru R, Suzuki K, Hida K, Miyasaka K, Iwasaki Y: Hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumor. J Neurooncol; 2006 May;78(1):63-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumor.
  • PURPOSE: To retrospectively analyze the outcome of post-operative radiotherapy for spinal cord glioma with the emphasis on the hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumors.
  • There were 12 low-grade astrocytic tumors, 11 high-grade astrocytic tumors, 16 low-grade ependymal tumors and 2 high-grade ependymal tumors.
  • Among 11 patients with high-grade astrocytic tumors, 5 with anaplastic astrocytoma and 1 with glioblastoma received hypofractionated radiotherapy boost for dose escalation.
  • RESULTS: The Kaplan-Meier survival rates at 10 years from the date of the first surgery were 64% for the entire group, 47% for the astrocytic tumors and 84% for the ependymal tumors, respectively (P=0.009).
  • Among 11 patients with high-grade astrocytic tumors, the actuarial survival rate at 10 years was 35%.
  • DISCUSSION: The results for ependymal tumors and low-grade astrocytic tumors were comparable to those reported in the literature.
  • Hypofractionated radiotherapy boost for dose escalation may help to prolong the survival of patients with high-grade astrocytic tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314938.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Whittemore DE, Grondahl RE, Wong K: Primary extraneural myxopapillary ependymoma of the broad ligament. Arch Pathol Lab Med; 2005 Oct;129(10):1338-42
Genetic Alliance. consumer health - Myxopapillary ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary extraneural ependymomas are rare tumors that arise in ectopic sites, including pulmonary, sacrococcygeal region, ovarian, and paraovarian tissues.
  • Here we describe a myxopapillary ependymoma of the broad ligament in a 22-year-old woman, which may be the first tumor of this type to be reported in this location.
  • Identification of perivascular ependymal rosettes, ependymal canals, vimentin and glial fibrillary acidic protein immunoreactivity, cytochemical staining of blepharoplasts or terminal bars by phosphotungstic acid hematoxylin, and presence of multiple foci of myxoid degeneration among the ependymal rosettes characterized a myxopapillary ependymoma.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Fibroma / diagnosis. Glial Fibrillary Acidic Protein / analysis. Granulosa Cell Tumor / diagnosis. Humans. Treatment Outcome. Vimentin / analysis

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196528.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


21. Sangoi AR, Lim M, Dulai M, Vogel H, Chang S: Suprasellar giant cell ependymoma: a rare neoplasm in a unique location. Hum Pathol; 2008 Sep;39(9):1396-401
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas are glial tumors that usually present in the posterior fossa in children and in the spinal cord in adults.
  • Giant cell ependymoma, a rare ependymal subtype only recently recognized as a diagnostic entity in the last decade, demonstrates pleomorphic giant cells admixed with features of typical ependymoma.
  • Moreover, as these neoplasms demonstrate a high incidence of anaplastic grade, recognition of this ependymal subtype is paramount.
  • We describe the presentation and pertinent radiologic, histologic, immunologic, and ultrastructural findings in conjunction with relevant clinical implications of the first reported case of a suprasellar giant cell ependymoma occurring in a 34-year-old female 7 years after an initial diagnosis of a medullary ependymoma with rare atypical giant cells, a potential tumor seeding culprit.
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602668.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Jung TY, Jung S, Jin SG, Jin YH, Kim IY, Kang SS, Kim SH: Prevention of postoperative subdural fluid collections following transcortical transventricular approach. Surg Neurol; 2007 Aug;68(2):172-6; discussion 176

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Subdural fluid collections appear in about 39% of patients after the removal of intra- and paraventricular tumors.
  • The authors retrospectively and prospectively studied the efficacy of gelfoam and fibrin adhesive in closing cortical and ependymal defects after intraventricular and/or paraventricular lesion resection to prevent the development of SFCs.
  • METHODS: From 1999 to 2004, we used gelfoam and fibrin adhesive on the cortical and ependymal defects of 28 patients who underwent the resection of intraventricular and/or paraventricular lesions via the transcortical approach associated with the communicated ventricle.
  • CONCLUSIONS: The use of gelfoam and fibrin adhesive to seal cortical and ependymal defects after a transcortical procedure might be a viable method of preventing the development of SFC.
  • [MeSH-minor] Adult. Aged. Cerebral Cortex / surgery. Cohort Studies. Ependyma / surgery. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662354.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrin Tissue Adhesive; 0 / Hemostatics; 0 / Tissue Adhesives
  •  go-up   go-down


23. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


24. Järvelä S, Nordfors K, Jansson M, Haapasalo J, Helén P, Paljärvi L, Kalimo H, Kinnula V, Soini Y, Haapasalo H: Decreased expression of antioxidant enzymes is associated with aggressive features in ependymomas. J Neurooncol; 2008 Dec;90(3):283-91
MedlinePlus Health Information. consumer health - Antioxidants.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to investigate the relationship between antioxidant enzyme expression and clinicopathological features in 67 ependymal tumors.
  • Their expression was studied in 46 primary (10 grade I, 30 grade II and 6 grade III) and 21 recurrent (3 grade I, 12 grade II and 6 grade III) tumors.
  • Immunoreactivity for MnSOD was found in 87%, GLCL-C in 74%, GLCL-R in 89%, Trx in 72%, TrxR in 54%, of primary tumors.
  • Lower GLCL-C and GLCL-R expression was associated with higher tumor grade (P = 0.047 and 0.049, respectively).
  • MnSOD, GLCL-C and TrxR expressions were significantly higher in tumors located in the spinal cord compared to those in the brain (P = 0.044, 0.046 and 0.004, respectively).
  • In the primary tumors Trx-positivity was found to correlate significantly with patient survival.
  • In univariate survival analysis patients whose tumors did not express Trx had shorter survival (P = 0.045) and there was even more significant association (P = 0.011) when only adults were included in the analysis (in the total material median follow-up time of Trx-positive tumors was 9.7 years and of Trx-negative 5.4 years).
  • The results indicate that AOEs have several biological functions in ependymal tumors.
  • Trx had important prognostic value: all adults with Trx-positive tumors were alive at follow-up (median 7.8 years).
  • [MeSH-minor] Adolescent. Adult. Aged. Chi-Square Distribution. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Superoxide Dismutase. Survival Analysis. Thioredoxin-Disulfide Reductase. Thioredoxins. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682894.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 52500-60-4 / Thioredoxins; EC 1.- / Oxidoreductases; EC 1.15.1.1 / Superoxide Dismutase; EC 1.8.1.9 / Thioredoxin-Disulfide Reductase
  •  go-up   go-down


25. Takano T, Akahira J, Moriya T, Murakami T, Tanaka M, Goto M, Niikura H, Ito K, Mikami Y, Okamura K, Yaegashi N: Primary ependymoma of the ovary: a case report and literature review. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1138-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymoma is a glioma with differentiation toward ependymal cells that usually arises in the central nervous system.
  • Microscopic examination revealed a highly cellular tumor composed of small cells with hyperchromatic, round-to-oval nuclei and scanty cytoplasm.
  • Perivascular pseudorosettes, ependymal rosettes, and extensive necrosis were observed.
  • Although rare, primary ovarian ependymoma must be kept in mind in the differential diagnosis of ovarian tumors, especially in young women.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Reoperation

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343197.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 16
  •  go-up   go-down


26. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, Perry A: Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol; 2005 Jul;18(7):991-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas are common pediatric and adult CNS malignancies with a wide biologic spectrum that is often hard to predict using classic prognostic variables.
  • The majority of cases harbored one or more detectable genetic alterations, but we found that 4.1B gene deletions and 4.1R loss of expression were statistically more common in the pediatric vs adult, intracranial vs spinal, and grade III vs grade I/II subsets (P-values of 0.038 to <0.001).
  • Also, 4.1G deletions were seen in 11/27 (41%) patients who either died of disease or had residual/recurrent tumor vs 5/41 patients with no evidence of disease at last follow-up (P=0.009).
  • We conclude that alterations of Protein 4.1 family members are common in ependymal tumors and that specific alterations are associated with distinct clinicopathologic subsets.
  • [MeSH-minor] Adolescent. Adult. Aged. Blood Proteins / analysis. Blood Proteins / genetics. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Cohort Studies. Cytoskeletal Proteins / analysis. Cytoskeletal Proteins / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Microfilament Proteins. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / genetics. Middle Aged. Neurofibromin 2 / analysis. Neurofibromin 2 / genetics. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism. Spinal Cord Neoplasms / pathology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731777.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Cytoskeletal Proteins; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Neurofibromin 2; 0 / Tumor Suppressor Proteins; 0 / erythrocyte membrane band 4.1 protein
  •  go-up   go-down


27. Mobley B, Kalani MY, Harsh GR 4th, Edwards MS, Vogel H: Papillary tumor of the spinal cord: report of 2 cases. Am J Surg Pathol; 2009 Aug;33(8):1191-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary tumor of the spinal cord: report of 2 cases.
  • Intramedullary spinal cord tumors constitute a small fraction of central nervous system tumors in the pediatric population; of these, the majority are ependymomas or astrocytomas.
  • We report 2 pediatric spinal cord tumor cases with unique morphologic and immunohistochemical features.
  • The first patient presented at age 7 with an intramedullary tumor of the thoracic spine.
  • The second patient presented at age 17 with an intramedullary tumor of the cervical spine.
  • The tumor recurred locally and in the cerebellum.
  • Electron microscopy showed ependymal differentiation.
  • The clinical features, including propensity for recurrence and remote subarachnoid spread, and the pathologic features of these tumors are reminiscent of papillary tumor of the pineal region, ependymoma, and choroid plexus papilloma.
  • The cases presented may constitute a new neoplastic entity within the recently described spectrum of central nervous system tumors with ependymal features.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Child. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Neurosurgical Procedures. Radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417584.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Wang M, Tihan T, Rojiani AM, Bodhireddy SR, Prayson RA, Iacuone JJ, Alles AJ, Donahue DJ, Hessler RB, Kim JH, Haas M, Rosenblum MK, Burger PC: Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol; 2005 Oct;64(10):875-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cerebral hemispheric tumors occurred in patients that were 3, 4, 12, 14, 15, 26, 30, and 37 years of age.
  • Histologically, the variably infiltrative tumors were distinctively angiocentric with well-developed perivascular pseudorosettes in some cases.
  • A glial nature was inferred from immunoreactivity for GFAP, and ependymal differentiation was suggested by positivity for EMA in three cases and ultrastructural features in one.
  • Overall, the tumors were biologically indolent except for one that recurred and ultimately proved fatal.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Ependymoma / pathology. Epilepsy / etiology. Glioma / complications. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy, Electron. Mucin-1 / metabolism


29. Chen Z, Ma L, Lou X, Zhou Z: Diagnostic value of minimum apparent diffusion coefficient values in prediction of neuroepithelial tumor grading. J Magn Reson Imaging; 2010 Jun;31(6):1331-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of minimum apparent diffusion coefficient values in prediction of neuroepithelial tumor grading.
  • PURPOSE: To retrospectively evaluate the diagnostic accuracy of diffusion weighted image (DWI) in the prediction of neuroepithelial tumors grading, and to appraise the apparent diffusion coefficient (ADC) value of neuroepithelial tumors with histologic findings as a reference standard.
  • MATERIALS AND METHODS: ADC values in 110 patients with pathologically proved neuroepithelial tumors, including 77 astrocytic tumors, 16 oligodendroglial tumors, 11 oligoastrocytic tumors, and 6 ependymal tumors, were investigated retrospectively.
  • The minimum ADC (MinADC) value of tumors was measured postoperatively on ADC maps, avoiding cystic, necrotic, or hemorrhagic components.
  • The area under the ROC curve (AUC) was 0.809, and the cutoff MinADC value of 0.900 x 10(-3) mm(2)/s for the differentiation between high and low grade neuroepithelial tumors provided the best combination of sensitivity (85.4%) and specificity (71.0%).
  • CONCLUSION: MinADC value may be a simple and effective optional tool for the prediction of neuroepithelial tumor grading.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diffusion. Female. Humans. Ki-67 Antigen / biosynthesis. Male. Middle Aged. ROC Curve. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Magn Reson Imaging. 2011 Mar;33(3):755; author reply 756 [21563262.001]
  • (PMID = 20512884.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


30. Roncaroli F, Consales A, Fioravanti A, Cenacchi G: Supratentorial cortical ependymoma: report of three cases. Neurosurgery; 2005 Jul;57(1):E192; discussion E192
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some tumors may extend to the gray matter reaching the pial surface, but pure cortical ependymomas are uncommon.
  • The three lesions represented 2.5% of all ependymal tumors and 21.4% of supratentorial tumors operated on during the study period.
  • All tumors were low grade.
  • CONCLUSION: Cortical ependymomas seem to behave as benign tumors amenable to surgical removal.
  • [MeSH-major] Brain Neoplasms / surgery. Ependymoma / surgery. Neurosurgery / methods. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Microscopy, Electron, Transmission / methods. Middle Aged. Radiotherapy / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987557.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. De Bustos C, Smits A, Strömberg B, Collins VP, Nistér M, Afink G: A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. J Med Genet; 2005 Jan;42(1):31-7
SciCrunch. OMIM: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Platelet derived growth factor receptor alpha (PDGFRalpha) expression is typical for a variety of brain tumours, while in normal adult brain PDGFRalpha expression is limited to a small number of neural progenitor cells.
  • METHODS AND RESULTS: We have investigated the link between single nucleotide polymorphisms (SNPs) within the PDGFRalpha gene promoter and the occurrence of brain tumours (medulloblastomas, supratentorial primitive neuroectodermal tumours (PNETs), ependymal tumours, astrocytomas, oligodendrogliomas, and mixed gliomas).
  • [MeSH-major] Brain Neoplasms / genetics. DNA-Binding Proteins / metabolism. Ependymoma / genetics. Neuroectodermal Tumors / genetics. Polymorphism, Single Nucleotide. Promoter Regions, Genetic. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 May 25;276(21):18082-9 [11278409.001]
  • [Cites] J Neurosci. 2001 May 15;21(10):3483-91 [11331377.001]
  • [Cites] Mol Cell Neurosci. 2001 Jun;17(6):1001-13 [11414789.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43713-22 [11559712.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3729-35 [12097282.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 23;296(3):604-11 [12176024.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 12;1588(3):254-60 [12393181.001]
  • [Cites] Blood. 2003 Feb 1;101(3):894-902 [12393719.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):172-6 [12524542.001]
  • [Cites] Mol Genet Metab. 2004 Feb;81(2):127-32 [14741194.001]
  • [Cites] Birth Defects Res C Embryo Today. 2003 Nov;69(4):272-85 [14745969.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 5;315(2):313-8 [14766209.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Sep;44(5):472-85 [2993532.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 May;51(3):272-80 [1316433.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1667-72 [7731723.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Nucleic Acids Res. 1995 Dec 11;23(23):4878-84 [8532532.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):712-23 [8552100.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):188-98 [8569181.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Pediatr Neurosurg. 1996;24(2):74-8 [8841077.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6644-53 [8943318.001]
  • [Cites] J Neurosci. 1997 Jan 1;17(1):125-39 [8987742.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4915-23 [9030551.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Apr 7;233(1):154-60 [9144414.001]
  • [Cites] Gene Expr. 1997;6(5):301-14 [9368101.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):484-94 [9417107.001]
  • [Cites] Mamm Genome. 1998 Feb;9(2):165-7 [9457682.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Mech Dev. 1998 Jan;70(1-2):167-80 [9510033.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):19955-64 [9685330.001]
  • [Cites] J Neurosci Res. 1998 Sep 1;53(5):521-30 [9726423.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5275-9 [9850047.001]
  • [Cites] Circ Res. 1999 Jan 8-22;84(1):64-73 [9915775.001]
  • [Cites] J Exp Med. 1999 May 17;189(10):1669-78 [10330446.001]
  • [Cites] FEBS Lett. 1999 May 7;450(3):268-72 [10359087.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] J Neurosci. 1999 Dec 1;19(23):10383-9 [10575035.001]
  • [Cites] Biochemistry. 2000 Apr 18;39(15):4347-57 [10757983.001]
  • [Cites] J Biol Chem. 2000 Apr 28;275(17):12879-88 [10777586.001]
  • [Cites] J Mol Med (Berl). 2000;78(5):287-92 [10954201.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30725-33 [10899165.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):215-7 [11175793.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):864-73; discussion 873-4 [11322447.001]
  • (PMID = 15635072.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / ZNF148 protein, human; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ PMC1735903
  •  go-up   go-down


32. Ginguené C, Champier J, Maallem S, Strazielle N, Jouvet A, Fèvre-Montange M, Ghersi-Egea JF: P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas. Brain Pathol; 2010 Sep;20(5):926-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) localize in the microvessels forming the blood-tumor barrier in ependymomas.
  • Ependymomas are neuroepithelial tumors that arise from the ependymal layer bordering the cerebral ventricles and spinal canal.
  • Intracranial ependymoma represents a major encephalic tumor in children, while spinal ependymoma develops more frequently in adults.
  • Real-time-PCR analysis showed that all three genes were expressed in all tumors, with no apparent correlation between the level of expression and either age or tumor grade.
  • The MRP1 transcript was expressed at a significantly higher level in spinal tumors than in intracranial tumors.
  • These data indicate that a biochemical, transporter-dependent blood-tumor barrier may exist in ependymomas, which may reduce the tumoral bioavailability of lipophilic and amphiphilic anticancer drugs.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Humans. Infant. Laminin / metabolism. Middle Aged. Models, Biological. P-Glycoproteins. Young Adult. von Willebrand Factor / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406235.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / ABCG2 protein, human; 0 / Laminin; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / von Willebrand Factor
  •  go-up   go-down


33. Jain D, Sharma MC, Sarkar C, Suri V, Rishi A, Garg A, Vaishya S: Chordoid glioma: report of two rare examples with unusual features. Acta Neurochir (Wien); 2008 Mar;150(3):295-300; discussion 300
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiologically, the paediatric chordoid glioma was located in the juxtaventricular region in the occipital horn of the lateral ventricle and was of mixed density whereas the adult patient had a typical third ventricle location with homogenous contrast enhancement.
  • Gross total surgical removal was achieved in both but the adult patient died post-operatively due to intra ventricular bleeding and bacterial meningitis.
  • Ultrastructural examination was suggestive of ependymal differentiation.
  • We propose that chordoid glioma is a variant of an ependymoma (WHO grade II) which arises from tanycytes and should be included in the WHO classification of brain tumors.
  • [MeSH-minor] Age Factors. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Child. Fatal Outcome. Female. Humans. Lateral Ventricles / pathology. Lateral Ventricles / radiography. Lateral Ventricles / surgery. Magnetic Resonance Imaging. Male. Meningitis, Bacterial / etiology. Neurosurgical Procedures / adverse effects. Postoperative Hemorrhage / etiology. Rare Diseases. Third Ventricle / pathology. Third Ventricle / radiography. Third Ventricle / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246456.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Kurimoto M, Nagai S, Hamada H, Tsuboi Y, Hayashi N, Kubota T, Endo S: Malignant transformation of supratentorial clear cell ependymoma. Neuropathology; 2009 Jun;29(3):299-302
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A brain tumor in the left frontal premotor area was removed and an initial pathological diagnosis of oligodendroglioma was made.
  • The tumor recurred 4 months later, and reoperation of the tumor and adjuvant local radiotherapy were performed.
  • The patient subsequently underwent surgical removal of recurrent tumors on another four occasions (6 times in total) during a period of 11 years and finally died of the original disease.
  • The first and second surgical specimens did not contain any ependymal rosettes or pseudorosettes, and thus a diagnosis of oligodendroglioma was made.
  • At this time, the tumor had an ultrastructural appearance compatible with ependymoma.
  • Thereafter, the recurrent tumors showed anaplastic features such as nuclear pleomorphisms and necrosis with pseudopallisading.
  • The autopsy specimens resembled a feature of glioblastoma but the tumor was sharply demarcated from the surrounding parenchyma.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Brain / pathology. Brain / ultrastructure. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647267.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Rumana M, Santosh V, Khursheed N, Yasha TC, Kolluri VR, Shetty S, Ravi KC: Primary spinal paragangliomas: a clinicopathological and immunohistochemical study of six cases. Indian J Pathol Microbiol; 2007 Jul;50(3):528-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All tumors were intradural in the cauda region one of them extending to the filum.
  • Gross total resection of tumors was possible in all cases.
  • Histologically four showed classical 'zell-ballen' pattern and two revealed an ependymal morphology.
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883124.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


36. Preusser M, Hoischen A, Novak K, Czech T, Prayer D, Hainfellner JA, Baumgartner C, Woermann FG, Tuxhorn IE, Pannek HW, Bergmann M, Radlwimmer B, Villagrán R, Weber RG, Hans VH: Angiocentric glioma: report of clinico-pathologic and genetic findings in 8 cases. Am J Surg Pathol; 2007 Nov;31(11):1709-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiocentric glioma has recently been described as a novel epilepsy associated tumor with distinct clinico-pathologic features.
  • We report the clinical and pathologic findings in 8 additional cases of this rare tumor type and extend its characterization by genomic profiling.
  • Cortico-subcortical tumors were located in the temporal and parietal lobes.
  • Histologically, the tumors were characterized by diffuse growth and prominent perivascular tumor cell arrangements with features of astrocytic/ependymal differentiation, but lacking neoplastic neuronal features.
  • Electron microscopy showed ependymal characteristics in 2 of 3 cases investigated.
  • All patients are seizure free and without evidence of tumor recurrence at follow-up times ranging from 1/2 to 6.9 years.
  • Our findings support 2 previous reports proposing that angiocentric glioma is a novel glial tumor entity of low-grade malignancy.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / ultrastructure. Epilepsy / genetics. Gene Expression Regulation, Neoplastic. Glioma / genetics. Glioma / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytes / pathology. Cell Differentiation. Cell Proliferation. Child. Child, Preschool. Chromosome Deletion. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 6. Ependyma / pathology. Europe. Female. Follow-Up Studies. Gene Dosage. Gene Expression Profiling / methods. Glial Fibrillary Acidic Protein / analysis. Humans. Magnetic Resonance Imaging. Male. Membrane Glycoproteins / analysis. Middle Aged. Mucin-1 / analysis. Nerve Growth Factors / analysis. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Receptor-Like Protein Tyrosine Phosphatases, Class 3 / genetics. S100 Calcium Binding Protein beta Subunit. S100 Proteins / analysis. Time Factors. Treatment Outcome. Vimentin / analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18059228.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Membrane Glycoproteins; 0 / Mucin-1; 0 / Nerve Growth Factors; 0 / PDPN protein, human; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human; 0 / Vimentin; EC 3.1.3.48 / PTPRJ protein, human; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 3
  •  go-up   go-down


37. Arai T, Tani S, Isoshima A, Nagashima H, Joki T, Takahashi-Fujigasaki J, Abe T: [Intraoperative photodynamic diagnosis for spinal ependymoma using 5-aminolevulinic acid: technical note]. No Shinkei Geka; 2006 Aug;34(8):811-7
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The fluorescence-guided resection using 5-aminolevulinic acid (5-ALA) is a well established method for the treatment of brain tumor, especially malignant glioma.
  • However, there is no report on photodynamic diagnosis (PDD) for spinal tumor.
  • Residual fluorescent samples taken from the tumor cavity were examined histologically RESULTS: Fluorescence peaked at 636nm in the removed tumors in all cases.
  • Fluorescent tissue tended to exist at the cranial and caudal portion in the tumor cavity or around the anterior median fissure.
  • The residual fluorescent tissue was not detected after removal of the tumor in case 1.
  • The residual fluorescent tissue was composed of tumor cells and ependymal lining in case 2 or the infiltrated inflammatory cells and vascular endothelial cells in case 3.
  • Postoperative magnetic resonance (MR) imaging showed no residual tumor in any of the cases.
  • CONCLUSION: The results of this study indicate the usefulness of 5-ALA-induced tumor fluorescence in guiding resection of spinal ependymoma.
  • 5-ALA-induced porphyrin fluorescence may label spinal ependymomas easily and clearly enough to enhance the completeness of tumor removal.
  • [MeSH-minor] Adult. Female. Fluorescence. Humans. Intraoperative Period. Lighting. Magnetic Resonance Imaging. Male. Middle Aged. Porphyrins. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910494.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


38. Azarpira N, Rakei M, Mokhtari M: Cytologic findings in malignant ependymoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):1023-6
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intraoperative imprint cytology has proved to be a valuable tool in the diagnosis of central nervous system (CNS) tumors.
  • Ependymomas are uncommon glial neoplasms of the CNS, arising from ependymal lining of the ventricular system and central canal of the spinal cord.
  • Anaplastic ependymoma is a rare tumor that causes diagnostic difficulties in imprint cytology because of variable cytomorphologic findings.
  • Computed tomography of the head showed hydrocephalus with a large parietal lobe tumor with midline structural shift.
  • The tumor showed pseudorosettes with glial fibrillary acidic protein and epithelial membrane antigen expression.
  • [MeSH-minor] Cell Aggregation. Fatal Outcome. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Rosette Formation. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053591.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


39. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Local radiotherapeutic management of ependymomas with fractionated stereotactic radiotherapy (FSRT). BMC Cancer; 2006;6:222

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 6 patients irradiation of the posterior fossa was performed with a local boost to the tumor bed, and in 4 patients the tumor bed only was irradiated.
  • In 7 patients FSRT was performed as re-irradiation for tumor progression.
  • All recurrent tumors were localized within the former RT-field.
  • Patients treated with FSRT for primary irradiation showed an overall survival of 100% and 78% at 3 and 5 years after irradiation of the posterior fossa with a boost to the tumor bed, and a survival rate of 100% at 5 years with RT of the tumor bed only.
  • CONCLUSION: The present analysis shows that FSRT is well tolerated and highly effective in the management of ependymal tumors.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / radiotherapy. Radiation Dosage. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1457-62 [3624024.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Nov;12(11):1937-41 [3771314.001]
  • [Cites] J Neurosurg. 1990 Mar;72(3):408-17 [2303876.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):723-45 [2323965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1497-502 [2262372.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2766-71 [2025840.001]
  • [Cites] Neurosurgery. 1991 May;28(5):659-64; discussion 664-5 [1876243.001]
  • [Cites] Neurosurgery. 1991 Aug;29(2):206-10 [1886658.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):313-9 [1587752.001]
  • [Cites] J Neurooncol. 1992 Jul;13(3):283-90 [1517804.001]
  • [Cites] Curr Opin Neurol Neurosurg. 1992 Dec;5(6):924-31 [1334739.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Neurooncol. 1993 Feb;15(2):125-31 [8509817.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):350-2; discussion 352-3 [8177398.001]
  • [Cites] Acta Neurochir (Wien). 1994;131(1-2):67-74 [7709787.001]
  • [Cites] Pediatr Neurol. 1996 Apr;14(3):216-19 [8736405.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):304-10 [9110291.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] Radiother Oncol. 1997 Oct;45(1):3-10 [9364625.001]
  • [Cites] Br J Neurosurg. 1997 Oct;11(5):421-8 [9474274.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):695-703 [9525716.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Radiologe. 1998 Mar;38(3):228-34 [9577869.001]
  • [Cites] Pediatr Neurosurg. 1998 Mar;28(3):135-42 [9705591.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):215-22 [9732252.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Semin Radiat Oncol. 1999 Jan;9(1):20-34 [10196396.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):721-31 [10201296.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):563-70 [10550587.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):287-95 [10661334.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):870-5 [10679657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):585-9 [10837939.001]
  • [Cites] J Neurol Sci. 2000 Aug 1;177(1):72-82 [10967185.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):605-13 [11014538.001]
  • [Cites] Surg Neurol. 2000 Jul;54(1):19-26; discussion 26 [11024503.001]
  • [Cites] Childs Nerv Syst. 2001 Feb;17(3):121-33 [11305764.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):117-22 [11943886.001]
  • [Cites] J Neurooncol. 2002 Jan;56(1):87-94 [11949831.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Oct;2(5):537-45 [12382522.001]
  • [Cites] J Neurosurg. 2002 Oct;97(4):827-35 [12405370.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1114-20 [12419438.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):187-90 [15015785.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1221-9 [15022290.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):255-61 [15332330.001]
  • [Cites] Strahlenther Onkol. 2004 Sep;180(9):590-6 [15378190.001]
  • [Cites] Cancer. 1975 Jun;35(6):1563-73 [1148991.001]
  • [Cites] J Neurosurg. 1976 Sep;45(3):273-83 [948014.001]
  • [Cites] Cancer. 1977 Aug;40(2):907-15 [890671.001]
  • [Cites] Strahlentherapie. 1980 Feb;156(2):97-101 [7355422.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):37-43 [7061255.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jul;8(7):1083-113 [6288633.001]
  • [Cites] Childs Brain. 1983;10(3):145-56 [6872622.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Aug;9(8):1121-4 [6874447.001]
  • [Cites] J Neurosurg. 1983 Oct;59(4):652-9 [6886786.001]
  • [Cites] Clin Radiol. 1984 Mar;35(2):163-6 [6697658.001]
  • [Cites] J Neurosurg. 1986 Feb;64(2):209-15 [3944630.001]
  • [Cites] Surg Neurol. 1988 Apr;29(4):271-81 [3353839.001]
  • (PMID = 16959039.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1584252
  •  go-up   go-down


40. Kawasaki K, Kohno M, Inenaga C, Sato A, Hondo H, Miwa A, Fujii Y, Takahashi H: Chordoid glioma of the third ventricle: a report of two cases, one with ultrastructural findings. Neuropathology; 2009 Feb;29(1):85-90
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chordoid glioma, which generally occurs in adults, is a rare CNS tumor arising in the anterior part of the third ventricle.
  • Both tumors showed essentially the same histological and immunohistochemical features; the tumors were composed of cords and nests of epithelioid, GFAP-immunoreactive cells in a mucinous stroma with lymphoplasmacytic infiltrates at the tumor periphery.
  • Ultrastructural examination in one case revealed that the tumor cells were characterized by the presence of hemidesmosomes and associated focal basal lamina formation, intermediate junctions, microvilli and cilia, and intercellular microrosettes with microvilli.
  • In the brain, the presence of fenestrated endothelial cells is a feature of the circumventricular organs (except the subcommissural organ), among which the organum vasculosum of the lamina terminalis is located in the anterior part of the third ventricular floor that is lined by specialized ependymal cells known as tanycytes.
  • [MeSH-minor] Adult. Basement Membrane / pathology. Blood Vessels / pathology. Cilia / pathology. Endothelial Cells / pathology. Ependymoma / pathology. Epithelioid Cells / pathology. Female. Glial Fibrillary Acidic Protein / analysis. Hemidesmosomes / pathology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Microscopy, Electron. Microvilli / pathology. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Neuropathology. 2009 Apr;29(2):208
  • (PMID = 18498285.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


41. Rushing EJ, Cooper PB, Quezado M, Begnami M, Crespo A, Smirniotopoulos JG, Ecklund J, Olsen C, Santi M: Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurooncol; 2007 Dec;85(3):297-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Subependymomas are rare ependymal neoplasms.
  • Tumors arose in the posterior fossa (n = 43), lateral ventricles (n = 37), spinal cord (2) and only one arose in the temporal horn.
  • Tumors ranged in size from 2.0 mm to 60 mm in greatest dimension (mean, 23.0 mm).
  • Eighteen-percent (15/83) of subependymomas exhibited a mixed histologic pattern; that is, subependymoma together with another glial tumor.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Infratentorial Neoplasms / pathology. Mixed Tumor, Malignant / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Cohort Studies. Female. Humans. Hydrocephalus / etiology. Hydrocephalus / pathology. Infant. Lateral Ventricles / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17569000.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Qian X, Goumnerova LC, De Girolami U, Cibas ES: Cerebrospinal fluid cytology in patients with ependymoma: a bi-institutional retrospective study. Cancer; 2008 Oct 25;114(5):307-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the frequency of CSF involvement in patients with ependymoma is unclear, and to the authors' knowledge the cytomorphologic features of the tumor cells have not been described in detail to date.
  • In this study, the CSF findings in patients with ependymal neoplasms are summarized and the cytomorphologic features of ependymoma, including its variants, are illustrated.
  • The detection rate of tumor cells in CSF was 6.7% in 15 adults and 21.2% in 33 children, with an overall rate of 16.7%.
  • Of the 8 patients with positive and/or suspicious diagnoses, 5 ependymomas exhibited anaplastic features and 1 tumor was a myxopapillary ependymoma.
  • CONCLUSIONS: Exfoliated cells from ependymomas are recognizable in CSF samples, especially in patients with myxopapillary tumors and tumors with anaplastic features.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Brain Neoplasms / pathology. Ependymoma / cerebrospinal fluid. Ependymoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies






Advertisement